ALK and non-small cell lung carcinoma: In kinase-addicted NSCLC, a reduction in tumor cell survival following EGFR- and ALK-directed therapy interventions could be counteracted by exposure to nonmalignant CAF populations or CAF-associated paracrine mediators [58–62].